Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $37.27, Implies 125% Upside
Syndax Pharmaceuticals' (SNDX) average price target was reduced from $37.55 to $37.27 by 11 analysts, with a range of $23 to $57. This implies a 125% upside from the Oct. 12 closing price. All 12 covering analysts maintain a 'Buy' rating.
How this was made
The 30-second read
Why it matters
The update is primarily sentiment and valuation framing rather than a new fundamental disclosure.
Market read
Traders may treat this as a minor sentiment update unless accompanied by new fundamental catalysts not mentioned here.
What to watch
Because the article provides no rationale for the target change, traders may need to check whether any underlying model assumptions or upcoming trial/regulatory milestones changed.
Background
This is an aggregator-style note summarizing analyst consensus price-target changes and ratings.
Ticker impact
The article says Syndax Pharmaceuticals’ average analyst price target fell from $37.55 to $37.27, with a $23 to $57 range.
Likely mild pressure or sideways trading as the market digests the lower average target, offset by the unchanged Buy consensus.
The only disclosed change is the average target level; the article does not cite new clinical, regulatory, or financial fundamentals, and consensus remains Buy (12 Buys, 0 Holds, 0 Sells).
Market effects
Minimal, since this is a single-name analyst-target adjustment without new biotech-specific catalysts.
None indicated.
None indicated.
Counterpoint
The wide target dispersion ($23 to $57) implies high uncertainty; the average cut may not reflect a durable thesis change.
Key entities
- companySyndax Pharmaceuticals, Inc.
Subject of the article, with analyst average price target cut to $37.27 and consensus rating remaining Buy.
